Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Medullary 2Neoplasm Metastasis 1

Interventions

pembrolizumab 107Specimen Handling 78Magnetic Resonance Spectroscopy 69Carboplatin 67Cisplatin 66Biopsy 57Nivolumab 56Radiotherapy 49Cyclophosphamide 49Paclitaxel 48durvalumab 37Gemcitabine 37Radiation 36Dexamethasone 32olaparib 31Etoposide 31Rituximab 30Docetaxel 30Doxorubicin 28atezolizumab 27Ipilimumab 27Lenalidomide 26Taxes 25Pemetrexed 24Bevacizumab 24Vincristine 23Platinum 23Cytarabine 23Radiotherapy, Intensity-Modulated 22Prednisone 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × vandetanib × 90 days × Clear all
NCT01298323 2026-04-17

Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment

Sanofi

Phase 3 Completed
205 enrolled 10 charts

Neoplasm Metastasis, Carcinoma, Medullary

NCT04211337 2026-03-19

LIBRETTO-531

Eli Lilly and Company

Phase 3 Active not recruiting
291 enrolled 16 charts 1 FDA

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡